Intravenous Immunoglobulin Industry Overview The global intravenous immunoglobulin market size is expected to reach USD 21.1 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2022 to 2030. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth. Intravenous Immunoglobulin Market Segmentation Grand View Research has segmented the global intravenous immunoglobulin market on the basis of application, distribution channel, and region: Based on the Application Insights, the market is segmented into Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome, Others.
Based on the Distribution Channel Insights, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, Others.
Intravenous Immunoglobulin Regional Outlook
Key Companies Profile & Market Share Insights This industry is witnessing a significant boost owing to the growing number of FDA approvals. Owing to this, a number of local and international players are investing in the IVIG business. Market players are adopting various strategies such as mergers and acquisitions, distribution, and other collaborative agreements to gain a greater share by increasing their market penetration. Some prominent players in the global intravenous immunoglobulin market include
Order a free sample PDF of the Intravenous Immunoglobulin Market Intelligence Study, published by Grand View Research.
0 Comments
Leave a Reply. |
Archives
December 2023
Categories |